Isavuconazonium Sulfate
FDA-approved product (capsule, oral), marketed as Cresemba.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Aspergillosis
- Mucormycosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Triazole and tetrazole derivatives
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J02AC05
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA64.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli45.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Isavuconazonium Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more47.8% AI-predicted activityagainst K. pneumoniae50+ registered studies
- Pafolacianine SodiumExisting use: Other diagnostic agents47.8% AI-predicted activityagainst K. pneumoniae1 registered study
- Rezafungin AcetateExisting use: Candidemia, Candidiasis, Candidiasis, Invasive47.6% AI-predicted activityagainst K. pneumoniae5 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection47.3% AI-predicted activityagainst K. pneumoniaeNo documented evidence found
- Ergoloid MesylatesExisting use: Cardiovascular disease47.1% AI-predicted activityagainst K. pneumoniae2 registered studies
- TrabectedinExisting use: Cancer, Dedifferentiated liposarcoma, Leiomyosarcoma and 7 more47.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
- LurbinectedinExisting use: Cancer, Neoplasm, Small cell lung carcinoma47.0% AI-predicted activityagainst K. pneumoniae50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more46.7% AI-predicted activityagainst K. pneumoniae35 registered studies
- Hydrocodone BitartrateExisting use: Cough, Drug dependence, Pain46.7% AI-predicted activityagainst K. pneumoniae50+ registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more46.4% AI-predicted activityagainst K. pneumoniae50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis46.1% AI-predicted activityagainst K. pneumoniae43 registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more46.1% AI-predicted activityagainst K. pneumoniae50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Drug Interaction Study of Isavuconazole and Cyclosporine
NCT01494597 · start 2011-11
Registered record
- Registry ID
- NCT01494597
- Conditions
- Healthy
- Interventions
- isavuconazole; cyclosporine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-11
- Completion
- 2011-12
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthyInterventionisavuconazole; cyclosporinePhasePhase 1Registry statusCompletedDrug Interaction Study of Isavuconazole and Midazolam
NCT01406171 · start 2011-05
Registered record
- Registry ID
- NCT01406171
- Conditions
- Pharmacokinetics of Isavuconazole; Pharmacokinetics of Midazolam; Healthy Volunteers
- Interventions
- Isavuconazole; Midazolam
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2011-05
- Completion
- 2011-06
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPharmacokinetics of Isavuconazole; Pharmacokinetics of Midazolam; Healthy VolunteersInterventionIsavuconazole; MidazolamPhasePhase 1Registry statusCompletedIsavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
NCT00634049 · start 2008-04-22
Registered record
- Registry ID
- NCT00634049
- Conditions
- Aspergillosis; Invasive Fungal Infections
- Interventions
- isavuconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2008-04-22
- Completion
- 2016-05-05
- Enrolment
- 149
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAspergillosis; Invasive Fungal InfectionsInterventionisavuconazolePhasePhase 3Registry statusCompletedIsavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
NCT00413218 · start 2007-03-08
Registered record
- Registry ID
- NCT00413218
- Conditions
- Candidiasis, Invasive; Candidemia; Mycoses
- Interventions
- Isavuconazole; Caspofungin; Voriconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-03-08
- Completion
- 2015-03-03
- Enrolment
- 450
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCandidiasis, Invasive; Candidemia; MycosesInterventionIsavuconazole; Caspofungin; VoriconazolePhasePhase 3Registry statusCompletedSafety, Efficacy and Pharmacokinetics of an Antifungal in Patients Undergoing Chemotherapy
NCT00413439 · start 2006-05
Registered record
- Registry ID
- NCT00413439
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Isavuconazole
- Study type
- INTERVENTIONAL
- Phase
- Phase 2 / Phase 3
- Registry status
- Completed
- Start
- 2006-05
- Completion
- 2007-06
- Enrolment
- 18
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAcute Myeloid LeukemiaInterventionIsavuconazolePhasePhase 2 / Phase 3Registry statusCompleted